Company intelligence / Profile preview

Adicet Bio

Redwood City, California, United Statesadicetbio.com ↗

Ownership: Public · ACET
Development stage: Phase 1

Overview

Currently conducting Phase 1 trials for ADI-001 in autoimmune diseases with preliminary data in lupus nephritis expected in 1H 2025. Also conducting Phase 1 trial for ADI-270 in metastatic/advanced clear cell renal cell carcinoma with preliminary data expected in 1H 2025.

Therapeutic areas: OncologyImmunology
Modalities: Allogeneic gamma delta T cell therapiesCAR T cell therapies
Industry: Biotech

Drug pipeline

13 assets

ADI-270

12 more assets in the full pipeline.

Request access →

Partnerships

Strategic collaboration with Regeneron Pharmaceuticals, Inc. (established in August 2016)

Financials

Market cap: $91M
Total revenue: $0
Enterprise value: $-14.4M

Beyond the preview

Go deeper on Adicet Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adicet Bio.

Explore the full profile